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ABSTRACT
Background: The Asthma Control Test (ACT) is frequently used for the evaluation of asthma control in clini-
cal care setting because it does not require the use of pulmonary function tests, which can be difficult for gen-
eral practitioners to use. However, few large-scale studies have investigated the efficacy of the Japanese ver-
sion ACT (J-ACT) in actual use during clinical care.
Methods: The aim of this study was to analyze the efficacy of the J-ACT in a clinical care setting. Using data
from a 2008 questionnaire survey including the J-ACT by the Niigata Asthma Treatment Study Group, we com-
pared the ACT scores of 2233 patients with respect to multiple parameters, including the severity by Japanese
Society of Allergology and the attack frequency. Using the definition of asthma control partially referred to
Global Initiative for Asthma (GINA) guidelines from the survey data, the accuracy screening and determination
of optimal ACT cutpoints were performed by retrospective analysis.
Results: Cronbach’s α for the J-ACT was 0.785. Patients with more severe asthma and more frequent asthma
attacks had lower ACT scores than did patients with less severe, less frequent attacks. The optimal ACT cut-
points were 24 for the controlled asthma and 20 for the uncontrolled asthma.
Conclusions: Our study, the first large-scale investigation of the efficacy of the J-ACT, determined that this
evaluation tool is highly efficacious in establishing the level of asthma control. However, the determination of
accurate cutpoints for the J-ACT will require more clear definitions of asthma control in future prospective stud-
ies.
KEY WORDS
ACT, asthma, control, cutpoints, efficacy
ABBREVIATIONS
ACT, Asthma Control Test; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IQR, interquartile
range; JSA, the Japanese Society of Allergology; PEFM, peak flow meter, ER: emergency room.
INTRODUCTION
The Global Initiative for Asthma (GINA) and Japa-
nese Society of Allergology (JSA) guidelines have
promoted the progression and the improvement of
asthma management.1-3 To use these guidelines ap-
propriately, it is extremely important to evaluate
asthma control in each patient because the treatment
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strategy essentially depends on the level of asthma
control.4,5 Studies of actual clinical care have indi-
cated that there is poor use of pulmonary function
tests,3,6-8 including forced expiratory volume at 1 sec-
ond peak expiratory flow (PEF), which are required
under most circumstances for proper evaluation of
asthma control under these guidelines. The Asthma
Control Test (ACT),9 developed in 2004, is a simple,
self-administrated, and rapidly completed assessment
tool consisting of 5 questions. This tool is recognized
as a superior for achieving asthma control.10-13 One of
the greatest benefits of ACT is that no respiratory
function tests are required to evaluate asthma con-
trol. The ACT is thus suitable for administration us-
ing questionnaire surveys for asthmatic patients and
is easy to use in the actual clinical care setting.
The Niigata Asthma Treatment Study Group has
been carrying out a regular questionnaire survey on
problems related to asthma management since 1998.
The subjects surveyed are adult patients with bron-
chial asthma who visited medical institutions in Nii-
gata Prefecture; the attending physicians of these pa-
tients are included in the survey. On the basis of
these surveys, we have reported the clinical charac-
teristics of adult bronchial asthma patients,14 bron-
chial asthma in the elderly,15 near-fatal asthma,16 peri-
menstrual asthma,17 the effect of obesity on asthma,18
factors that exacerbate asthma,19 the selection of in-
haled corticosteriods,20 the relationship between
smoking and gender in asthmatics,21 and changes in
asthma management.1-3
Although the Japanese version the ACT (J-ACT)
was established in 2006, there have been few large-
scale reports on its the efficacy in the actual clinical
care setting. In this study, the Niigata Asthma Treat-
ment Study Group carried out a questionnaire-based
survey to investigate the efficacy of the J-ACT. A ret-
rospective analysis was performed to determine the
cutpoints of the J-ACT using the results obtained
from the surveys.
METHODS
Participation in this study was open to all medical in-
stitutions in Niigata Prefecture if they intended to join
the Niigata Asthma Treatment Study Group. This
study was performed with the approval of the Ethics
Committee at the School of Medicine of Niigata Uni-
versity (#701) in Niigata Prefecture, Japan, or the par-
ticipating institution, in accordance with the Ethical
Principles for Medical Research Involving Human
Subjects (Declaration of Helsinki). Written informed
consent was obtained from all of the patients. The
study involved 28 large hospitals (200 beds or more),
14 small hospitals (less than 200 beds), and 62 clinics
(no beds). A total of 5260 questionnaires were pre-
pared, and 3146 responses were received (response
rate: 59.8%). The contents of the questionnaire were
written in Japanese. The questionnaire study was per-
formed over 2 months from September to October
2008. Subjects were adult patients (aged 16 years or
more) with bronchial asthma who regularly visited
the participating institutions for asthma management
(typically once or twice per month). The recruited pa-
tients were asked to complete the questionnaire by
themselves. Individual patients were therefore ex-
pected to understand technical terms such as “attack”
in the questionnaire. This questionnaire also included
the J-ACT.
In addition to the J-ACT, patients were asked about
their peak flow meter (PEFM) use, smoking status,
and the incidence of asthma attacks during the 2
weeks prior to answering the questionnaire. The
questionnaire included questions on asthma-related
symptoms during the last 2 weeks before completing
the questionnaire, including those regarding cough
and sputum in the morning and at night, and sleep
disturbances. The patients were also asked a series of
questions to evaluate their condition during the year
before completing the J-ACT questionnaire. The con-
tents of the questionnaire to each patient except the J-
ACT were shown in Table 1. In addition to monitor-
ing the completion of the questionnaire by the pa-
tient, physicians were asked to supply details on cur-
rent treatment, medication used for primary control,
the type of asthma (atopic or non-atopic) as indicated
by total serum IgE or detection of a specific IgE for
allergens, and the severity of asthma in accordance
with the JSA guidelines “Asthma Prevention and
Management Guideline 2006, Japan” (in Japanese).
The severity by JSA guideline 2006 is defined as fol-
lows. In Step 1, appearance rate of symptoms is less
than 1 timeweek and no continuous medication such
as inhaled corticosteroids (ICSs) is basically re-
quired. In Step 2, appearance rate of symptoms is not
everyday but more than 1 timeweek and low doses
of ICSs is regularly required. In Step 3, appearance
rate of symptoms is everyday and middle doses of
ICSs and other controllers are regularly required. In
Step 4, appearance rate of symptoms is everyday and
activity of the daily living impaired under high doses
of ICSs and other controllers.
All questionnaires were collected to the authors,
and the authors calculated the ACT scores. To evalu-
ate the efficacy of the J-ACT, the Cronbach’s α value
was calculated. Based on the questionnaire survey
mentioned above, each patient was retrospectively
evaluated with respect to the following criteria: (1)
the severity of asthma based on the 2006 JSA guide-
lines, classified as Step1, 2, 3 and 4; (2) frequency of
asthma attacks during the year before completing the
questionnaire, classified as “few”, “seasonal” and
“persistent”; (3) the frequency of asthma attacks dur-
ing the last 2 weeks before completing the question-
naire, classified as none, 1-2 timesweek, 3-4 times
week and 5-7 timesweek; (4) the appearance of
morning and nocturnal symptoms related to asthma
Efficacy of the Asthma Control Test
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Table　1　Questionnaire administered to asthmatic patients (original in Japanese)
Age:          years old          Gender: male / female
Question 1
When were you fi rst diagnosed as having bronchial asthma?    Year:     Month:     Day:     
Question 2
1) Select which of the following applies to you:
(I do not smoke, I am an ex-smoker, I currently smoke)
2) If you are an ex-smoker, please answer followings:
 At what age did you start smoking? The age you started:
 At what age did you stop smoking? The age you stopped:
 How many cigarettes did you smoke per day? Cigarettes/day (on average):
 Did you stop smoking due to your asthma? Yes or No:
3) If you currently smoke, please answer the following:
 How old were you when you started smoking? The age you started:
 How many cigarettes did you smoke per day? Cigarettes/day (on average):
Question 3
1) Do you use a peak-fl ow meter? Yes or No
2) What was your average peak fl ow rate when using your meter during the last 2 weeks?
 Morning:          Night:
Question 4    Select one answer for each the following questions:
1) How often did you have asthma attacks during the last 12 months?
(frequent attacks, seasonal attacks, or few attacks)
2) How often did you have asthma attacks during the last 2 weeks?
(5-7/week, 3-4/week, 1-2/week, or none)
3) How severe were your asthma attacks during the last 2 weeks?
(impossible to move, impossible to lie down, possible to lie down, stridor, dyspnea upon exertion)
4) Have you ever been hospitalized due to asthma? 
(yes/no)
5) Have you ever been taken by ambulance or visited an emergency room due to an attack ? 
(yes/no)
6) Have you ever been placed on a respirator due to an asthma attack? 
(yes/no)
7) Have you ever been unconscious due to an asthma attack? 
(yes/no)
8) Have you ever had an attack induced by anti-infl ammatory drugs, including painkillers, antipyretics, or cold medicine?
9) Were you absent from work or school due to an asthma attack during the last 12 months? 
(yes/no)
Question 5
How bad was your asthma during the last 2 weeks?
(very good, fairly good, mediocre, slightly bad, or bad)
Question 6
Describe your symptoms during the last 2 weeks:
1) In the morning 
(cough, sputa, chest tightness, stridor, dyspnea, or no symptoms)
2) At night 
(cough, sputa, chest tightness, stridor, dyspnea, or no symptoms)
3) Sleep disturbance 
(sometimes cannot fall asleep due to dyspnea, cannot have a good sleep due to dyspnea, waking up in the night due to 
chest tightness, or none)
Question 7
Do you feel satisfi ed with your daily life? 
(very satisfi ed, fairly satisfi ed, mediocre, slightly dissatisfi ed, or dissatisfi ed)
during the last 2 weeks before completing the ques-
tionnaire, classified as symptom (-) and symptom (+);
(5) the existence of sleep disturbance during the last
2 before completing the questionnaire, classified as
sleep disturbance (-) and sleep disturbance (+); (6)
the existence of work absenteeism during the year
before completing the questionnaire; (7) emergency
services required, classified as ambulance use or ER
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Table　2　Background and characteristics of study participants
Cases 2233
Age (years) 54.2 ± 18.3
Gender (male/female, %) 42.5/55.9
Disease duration (years) 14.1 ± 14.0
PEFM Use (%) 26.1
Smoking status 
non-smoker (%) 52.4
ex-smoker (%) 28.7
current smoker (%) 16.3
Disease type (atopic/non-atopic, %) 67.6/26.5
Asthma attack rate during the last 2 weeks PQ (%) 25.9
Morning symptom rate during the last 2 weeks PQ (%) 43.7
Nocturnal symptom rate during the last 2 weeks PQ (%) 30.9
Sleep disturbance rate during the last 2 weeks PQ (%) 14.8
Disease severity (step 1, 2, 3, or 4 [%]) 24.9, 28.8, 26.3, 5.2
Persistent symptoms during the past year PQ (%)  9.7
Work absenteeism rate during the past year PQ (%)  9.8
ICS use rate (%) 86.1
OCS use rate (%)  4.8
LABA use rate (%) 38.3
LTRA use rate (%) 43.5
OSRT use rate (%) 43.8
Ambulance use or ER visit rate (%) 32.0
Hospitalization (%) 34.4
ACT score (median [IQR]) 23 [20-24]
PEFM, peak expiratory fl ow meter; ICS, inhaled corticosteroids; LABA, long-acting beta agonist; LTRA, leukotriene receptor antagonist; 
OSRT, oral sustain-released theophylline; ER, emergency room; PQ, prior to the questionnaire; ACT, Asthma Control Test; IQR, interquar-
tile range.
visit (-) and ambulance use or ER visit (+); and (8) the
need for hospitalization, classified as hospitalization
(-) and hospitalization (+). Patients were divided into
groups based on their responses to each category,
and the ACT scores of the groups were compared
and analyzed.
Because the aim of the J-ACT performance in this
survey was not to evaluate the efficacy of the J-ACT
but to use the J-ACT for asthma control of each pa-
tient, there was inadequate information for the estab-
lished asthma control status criteria such as that by
GINA 2006. The status of asthma control was tried to
be defined basically according to the GINA 2006
guidelines: (1) controlled asthma, in which a patient
had asthma attacks no more than 3 timesweek in the
frequency of asthma attacks, no morning or nocturnal
symptoms related to asthma, and no sleep distur-
bances during the 2 weeks before answering the
questionnaire; (2) uncontrolled asthma, in which a
patient had asthma attacks more than 2 timesweek
and symptoms that included sleep disturbances or
morning or nocturnal symptoms related to asthma
during the 2 weeks before completing the question-
naire. Using this definition, screening performance
for the J-ACT was analyzed.
Results for continuous variables, except the ACT
scores, were expressed as arithmetic means and stan-
dard deviations. ACT scores were expressed as me-
dian value and interquartile ranges (IQRs). Inter-
group differences in terms of continuous variables
were evaluated using the Kruskal-Wallis test and
Mann-Whitney U test with the Bonferroni correction.
All statistical analyses were performed using the sta-
tistical software StatView 5.0 PowerPC version (SAS
Institute Inc., Cary, NC, USA). For all statistical analy-
ses, a P-value of <0.05 was considered to be signifi-
cant.
RESULTS
PATIENT CHARACTERISTICS
Patient characteristics are summarized in Table 2.
We excluded the cases that incompletely responded
to both the 5 questions of the J-ACT and the 4 ques-
tions need to evaluate asthma control by our criteria.
Of the 3146 asthmatic patients who completed the
questionnaire, 2233 were analyzed in this study. The
age (mean ± SD), gender (malefemale [%]), disease
duration (mean ± SD), disease type (atopicnon-
atopic [%]), and the rate of peak-flow meter use were
54.2 ± 18.3 years, 42.5％55.9%, 14.1 ± 14.0 years,
Efficacy of the Asthma Control Test
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Table　3　Correlation between ACT scores and asthma severity
Step 1 Step 2 Step 3 Step 4
Numbers of patients 557 643 587 117
ACT score (median [IQR]) 24 [21-25] 23 [20-24]* 22 [19-24]*,*** 21 [18-24]*,**
ACT, Asthma Control Test; IQR, interquartile range; *p < 0.001 vs. Step 1; **p < 0.01; ***p < 0.001 vs. Step 2.
Table　4　Correlation between ACT scores and asthma attack frequency during the last year before completing the questionnaire
Few attacks Seasonal attacks Persistent attacks
Numbers of patients 971 837 217
ACT score (median [IQR]) 24 [23-25] 22 [19-24]* 18 [15-21]*,**
ACT, Asthma Control Test; IQR, interquartile range; *p < 0.001 vs. few attacks; **p < 0.001 vs. seasonal attacks.
Table　5　Correlation between ACT scores and asthma attack frequency during the last 2 weeks before completing the ques-
tionnaire
None 1-2 times/week 3-4 times/week 5-7 times/week
Numbers of patients 1654 337 129 73
ACT score (median [IQR]) 24 [22-25] 20 [17-21]* 16 [13-19]*,** 15 [11-18]*,**
ACT, Asthma Control Test; IQR, interquartile range; *p < 0.001 vs. None; **p < 0.001 vs. 1-2 times/week.
67.6％26.5% and 26.1%, respectively. Rates of non-
smokers, ex-smokers, and current smokers were
52.4%, 28.7% and 16.3%, respectively. The attack rate
during the 2 weeks before answering the question-
naire was 25.9%, and rates of morning symptoms, noc-
turnal symptoms and sleep disturbance were 43.7%,
30.9% and 14.8%, respectively. The rates of persistent
symptoms and absenteeism from work during the
year before answering the questionnaire were 9.7%
and 9.8%, respectively. The rate of use of ICSs was
over 80%, whereas rates for use of long-acting beta ag-
onists, leukotriene receptor antagonists, and oral
sustained-released theophylline were around 40%.
Oral corticosteroids were used by less than 5% of the
patients. The rate of ambulance use or ER visits was
32.0%, and hospitalization was required for 34.4% of
the patients. The median ACT scores [IQR] were 23
[20-24].
EFFICACY OF ACT
Cronbach’s α was 0.785, indicating an acceptable in-
ternal consistency in the answers to the 5 questions
of the J-ACT questionnaire. Comparing the groups
with different asthma severities, the ACT scores were
significantly lower in patients with Step 2, Step 3, and
Step 4 than in those with Step 1 asthma; the ACT
scores were significantly lower in patients with Step 3
and 4 asthma than in those with Step 2 asthma (Table
3). The ACT scores in patients with seasonal and per-
sistent attacks were significantly lower than those in
patients who experienced few attacks; the ACT
scores in patients with persistent attacks were signifi-
cantly lower than those in patients with seasonal at-
tacks (Table 4). All patients who had asthma attacks
1-2, 3-4 or 5-7 timesweek during the 2 weeks before
completing the questionnaire had significantly lower
ACT scores than those who had no asthma attacks
during this period. The ACT scores of patients who
had asthma attacks 3-4 and 5-7 timesweek were sig-
nificantly lower than those of patients who had
asthma attacks 1-2 timesweek during the same pe-
riod (Table 5). The ACT scores were significantly
lower in patients who experienced morning and noc-
turnal symptoms and sleep disturbances than in pa-
tients who did not (Table 6a, b, c). The ACT scores
were significantly lower in patients who required am-
bulance use or ER visits than in those who did not
(Table 7a, b). The ACT scores were significantly
lower in patients who scored positive for absenteeism
than in those who did not (Table 7c).
SCREENING ACCURACY AND DETERMINATION
OF OPTIMAL ACT CUTPOINTS
The performance of the ACT scores for screening pa-
tients with controlled asthma is summarized in Table
8, where the ACT scores represent different pro-
posed cutpoints. Cutpoints of <15 yielded poor ACT
classification accuracy and were therefore dismissed.
The Youden index reached the maximum (0.503) at
an ACT score of 24; therefore, we used an ACT score
of 24 as the optimal cutpoints for screening patients
with controlled asthma. As seen from the ROC curve,
a cutpoint of 24 represents the point closest to the left
top corner (Fig. 1), yielding the lowest rates of false-
positive and false-negative screening results. The
screening performance of ACT scores for identifying
Hasegawa T et al.
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Table　6　Correlation between ACT scores and morning symptoms during the last 2 weeks before completing the questionnaire
a)
Symptoms (-) Symptoms (+)
Numbers of patients 1257 976
ACT score (median [IQR]) 24 [22-25] 20 [17-23]*
ACT, Asthma Control Test; IQR, interquartile range; *p < 0.001 vs. Symptoms (-).
b)
Symptoms (-) Symptoms (+)
Numbers of patients 1543 690
ACT score (median [IQR]) 24 [22-25] 19 [16-22]*
ACT, Asthma Control Test; IQR, interquartile range; *p < 0.001 vs. Symptoms (-).
c)
Sleep disturbance (-) Sleep disturbance (+)
Numbers of patients 1900 330
ACT score (median [IQR]) 24 [21-25] 17 [13-20]*
ACT, Asthma Control Test; IQR, interquartile range; *p < 0.001 vs. Sleep disturbance (-).
Table　7　
a) Correlation between ACT scores and ambulance use or ER visit
Ambulance use or ER Visit (-) Ambulance use or ER Visit (+)
Numbers of patients 1470 714
ACT score (median [IQR]) 23 [20-25] 23 [19-24]*
ACT, Asthma Control Test; ER, emergency room; IQR, interquartile range; *p < 0.001 vs. Ambulance use or ER Visit (-).
b) Correlation between ACT scores and hospitalization
Hospitalization (-) Hospitalization (+)
Numbers of patients 1390 769
ACT score (median [IQR]) 23 [20-25] 23 [19-24]*
ACT, Asthma Control Test; IQR, interquartile range; *p < 0.01 vs. Hospitalization (-).
c) Correlation between ACT scores and work absenteeism during the last year before completing the questionnaire
Work absenteeism (-) Work absenteeism (+)
Numbers of patients 1906 218
ACT score (median [IQR]) 23 [20-25] 20 [16-23]*
ACT, Asthma Control Test; IQR, interquartile range; *p < 0.001 vs. Work absenteeism (-).
Table　8　Screening performance of ACT for identifying controlled asthma at different cutpoints
ACT score 
cutpoints (≤)
Sensitivity 
(%)
Specifi city 
(%)
Positive predictive 
value (%)
Negative predictive 
value (%)
Youden 
index 
Area under 
ROC
25 41.5 91.8 83.6 61.0 0.333 0.667
24 68.6 81.8 79.1 72.1 0.503 0.752
23 79.1 69.6 72.3 76.8 0.487 0.743
22 88.1 60.6 69.2 83.5 0.487 0.744
21 93.0 50.8 65.5 87.9 0.438 0.719
20 96.5 40.0 61.8 92.0 0.366 0.683
19 97.9 31.2 58.9 93.5 0.291 0.645
18 98.4 26.5 57.4 94.2 0.249 0.624
17 99.0 20.6 55.6 95.4 0.196 0.598
16 99.1 16.4 54.4 94.8 0.155 0.577
15 99.3 12.3 53.3 94.5 0.116 0.558
Efficacy of the Asthma Control Test
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Table　9　Screening performance of ACT for identifying uncontrolled asthma at different cutpoints
ACT score 
cutpoints (≤)
Sensitivity 
(%)
Specifi city 
(%)
Positive predictive 
value (%)
Negative predictive 
value (%)
Youden 
index 
Area under 
ROC
15  39.7 96.6 51.7  94.5 0.363 0.681
16  50.3 95.3 49.5  95.4 0.445 0.728
17  58.7 93.7 46.3  96.1 0.524 0.762
18  68.3 91.0 41.3  96.9 0.593 0.797
19  75.1 88.7 38.2  97.5 0.639 0.819
20  85.7 84.2 33.4  98.5 0.699 0.850
21  90.5 76.9 26.6  98.9 0.673 0.837
22  96.8 69.4 22.6  99.6 0.662 0.831
23  97.4 59.6 18.2  99.6 0.570 0.785
24  99.5 47.4 14.9  99.9 0.469 0.734
25 100.0 27.2 11.3 100.0 0.272 0.636
Fig.　1　ROC curve of the ACT for assessing controlled 
asthma. ○: cutpoints; arrow: cutpoint 24, indicating the defi -
nition of controlled asthma: a patient who had asthma at-
tacks no more than 3 times/week, no morning or nocturnal 
symptoms related to asthma, and no sleep disturbances dur-
ing the 2 weeks before answering the questionnaire.
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Fig.　2　ROC curve of the ACT for assessing uncontrolled 
asthma. ○: cutpoints; arrow: cutpoint 20, indicating the defi ni-
tion of uncontrolled asthma: a patient with asthma attacks 
more frequent than 2 times/week and symptoms that included 
sleep disturbance or morning or nocturnal symptoms related 
to asthma during the 2 weeks before completing the ques-
tionnaire.
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uncontrolled asthma is summarized in Table 9. Cut-
points of <15 yielded poor ACT classification accuracy
and were therefore dismissed. With the Youden in-
dex reaching the maximum of 0.699, the correspond-
ing ACT score of 20 served as the optimal cutpoints
for screening patients with uncontrolled asthma. The
ROC curve demonstrates that a cutpoint of 20 repre-
sents the point closest to the top left top corner (Fig.
2). By ACT scoring, the asthma was controlled at a
score of >=24 and uncontrolled at a score of =<20.
DISCUSSION
The aim of this study was to confirm the efficacy of
the J-ACT in the actual clinical care. An efficacious
asthma evaluation tool must enable not only asthma
specialists but also general physicians to accurately
assess patients with asthma. Considering a huge bur-
den of requirement for asthma management,22-24 it
would be helpful if general physicians could play a
more central role in the clinical care of these patients.
The ACT was found to be one of the most suitable
tools for general physicians to assess asthma control,
Hasegawa T et al.
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as guidelines such as GINA and JSA require the
evaluation of respiratory function,4,5 which general
physicians found to be difficult.6-8 The ACT is thus
suitable for management of asthmatic patients by
general physicians.
The value of Cronbach’s α clearly showed that the
J-ACT is reliable. The calculation of Cronbach’s α cal-
culation was performed even in this study because
there were no published reports in English about the
reliability and the validity of the J-ACT. Table 3-7
clearly demonstrates the efficacy of the J-ACT. In par-
ticular, disease severity based on JSA was deter-
mined by each patient’s physician5 (Table 3), and
asthma attack frequency during the year before com-
pleting the questionnaire was self-rated by each pa-
tient (Table 4); these evaluations were completely in-
dependent of the 5 questions used in the J-ACT.
These 2 results clearly confirm the validity of the J-
ACT. The correlation between the J-ACT scores and
ambulance use or ER visit, hospitalization and work
absenteeism in Table 7 might be important in the effi-
cacy of the J-ACT because these results can be indi-
cate the correlation between so-called future risk and
J-ACT scores.
There was 1 major limitation of this study related
to the definition of controlled and uncontrolled
asthma; this could have affected screening accuracy
and determination of optimal ACT cutpoints. Because
the analysis was retrospective, the level of asthma
control was not classified at the time of the survey.
Therefore, the definition of asthma control was deter-
mined according to the GINA guidelines4 using the
survey data. One item used in defining controlled
asthma in this study was a lack of morning and noc-
turnal symptoms related to asthma and no sleep dis-
turbances during the 2 weeks before completing the
questionnaire. This item was used instead of the
GINA item, indicating no nocturnal symptoms or
awakening. Another item used in this study to define
controlled asthma was a frequency of asthma attacks
of no more than 3 timesweek; this indicator was
used instead of the GINA item, specifying that the
frequency of asthma symptoms in the daytime be no
more than 3 timesweek. Additionally, there were no
further items concerning each patient’s condition and
no evaluation of respiratory function in our definition
of asthma control. Therefore, the number of cases of
controlled asthma determined by this definition may
have been overestimated compared to that deter-
mined using GINA guidelines. In that case, some un-
controlled patients according to the GINA definition
could have been classified as controlled by our defini-
tion; this discrepancy between the 2 definitions might
affect the determination of the optimal cutpoints for
the ACT.
Although there were no established cutpoints for
controlled asthma, the ACT score was often used as a
tool for the detection of controlled asthma when the
cutpoint was 20 for the J-ACT. This implies that man-
agement of asthma should not be changed when the
ACT score is >=20. Studies have proposed that the
cutpoint of 20 for ACT corresponds to the strategy of
asthma management as put forth in the GINA and
JSA guidelines.4,5 However, the results of our analysis
indicate that it would be better to use a score of 24
rather than a score of 20 as a cutpoint to achieve com-
plete control of asthma using all conventional medi-
cines under these guidelines. Use of 20 as a cutpoint
might be against the strategy of asthma management
proposed by GINA or JSA. Given the difference in
definitions of “controlled asthma” as mentioned
above, a cutpoint above 24 might be necessary as an
adequate cuopoint for controlled asthma, and a cut-
points of 20 should not be used for controlled asthma.
On the other hand, we propose another method for
using these guidelines. If the cutpoints for the J-ACT
was used only for the detection of uncontrolled
asthma, a cutpoint of 20 is likely to be suitable. To de-
termine the cutpoints for the J-ACT, a prospective
study using an established definition of asthma con-
trol will be required.
In summary, we established the efficacy of the J-
ACT using a questionnaire survey; the J-ACT elimi-
nated the need for respiratory function tests and was
suitable for use by general physicians administering
clinical care. This study is the first large-scale investi-
gation to report of the efficacy of the J-ACT. However,
there was a disadvantage in assigning cutpoints in the
J-ACT. Although cutpoints of 24 and 20 were indi-
cated for controlled asthma and uncontrolled asthma,
respectively, a further prospective study using an es-
tablished definition for asthma control based on
GINA or JSA will be required for definitive establish-
ment of cutoff values.
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